Salvia divinorum and Salvinorin A: An Update on Pharmacology and Analytical Methodology

Abstract

Salvia divinorum L. (Lamiaceae) has been used for centuries by the Mazatecan culture and has gained popularity as a recreational drug in recent years. Its potent hallucinogenic effects seen in case reports has triggered research and led to the discovery of the first highly selective non-nitrogenous κ opioid receptor agonist salvinorin A. This review critically evaluates the reported pharmacological and toxicological properties of S. divinorum and one of its major compounds salvinorin A, its pharmacokinetic profile, and the analytical methods developed so far for its detection and quantification. Recent research puts a strong emphasis on salvinorin A, which has been shown to be a selective opioid antagonist and is believed to have further beneficial properties, rather than the leaf extract of S. divinorum. Currently animal studies show a rapid onset of action and short distribution and elimination half-lives as well as a lack of evidence of short- or long-term toxicity. Salvinorin A seems to be the most promising approach to new treatment options for a variety of CNS illnesses. However, many further investigations are necessary to fully understand and elucidate the various medicinal properties of the plant itself and to provide the legislative authorities with enough information to cast judgement on S. divinorum.

Abbreviations

CNS: central nervous system

FST: forced swimming test

i. t.: intrathecal

KOR: kappa opioid receptor

LSD: lysergic acid diethylamide

norBNI: norbinaltorphimine

p. o.: per os

s. c.: subcutaneous

ssp.: subspecies

Salvia divinorum - Lamiaceae - depression - opioid antagonist - pharmacokinetics - pharmacology - toxicology - salvinorin A

References

• 1 Epling C, Jativa M C. A new species of Salvia from Mexico.  Bot Mus Leafl Harv Univ. 1962;  20 75-6.
• 2 Sheffler D J, Roth B L. Salvinorin A: the ”magic mint” hallucinogen finds a molecular target in the kappa opioid receptor.  Trends Pharmacol Sci. 2003;  24 107-9.
• 3 Siebert D J. Salvia divinorum and salvinorin A: new pharmacologic findings.  J Ethnopharmacol. 1994;  43 53-6.
• 4 Valdes  3rd L J. Salvia divinorum and the unique diterpene hallucinogen, Salvinorin (divinorin) A.  J Psychoactive Drugs. 1994;  26 277-83.
• 5 Giroud C, Felber F, Augsburger M, Horisberger B, Rivier L, Mangin P. Salvia divinorum: an hallucinogenic mint which might become a new recreational drug in Switzerland.  Forensic Sci Int. 2000;  112 143-50.
• 6 Halpern J H. Hallucinogens and dissociative agents naturally growing in the United States.  Pharmacol Ther. 2004;  102 131-8.
• 7 Prisinzano T E. Psychopharmacology of the hallucinogenic sage Salvia divinorum .  Life Sci. 2005;  78 527-31.
• 8 Bertea C M, Luciano P, Bossi S, Leoni F, Baiocchi C, Medana C. et al . PCR and PCR-RFLP of the 5S-rRNA-NTS region and salvinorin A analyses for the rapid and unequivocal determination of Salvia divinorum .  Phytochemistry. 2006;  67 371-8.
• 9 Imanshahidi M, Hosseinzadeh H. The pharmacological effects of Salvia species on the central nervous system.  Phytother Res. 2006;  20 427-37.
• 10 Roth B L, Lopez E, Beischel S, Westkaemper R B, Evans J M. Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery.  Pharmacol Ther. 2004;  102 99-110.
• 11 O’Connor K A, Roth B L. Screening the receptorome for plant-based psychoactive compounds.  Life Sci. 2005;  78 506-11.
• 12 Yan F, Mosier P D, Westkaemper R B, Stewart J, Zjawiony J K, Vortherms T A. et al . Identification of the molecular mechanisms by which the diterpenoid salvinorin A binds to kappa-opioid receptors.  Biochemistry. 2005;  44 8643-51.
• 13 Butelman E R, Harris T J, Kreek M J. The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys.  Psychopharmacology (Berl). 2004;  172 220-4.
• 14 Butelman E R, Mandau M, Tidgewell K, Prisinzano T E, Yuferov V, Kreek M J. Effects of salvinorin A, a {kappa}-opioid hallucinogen, on a neuroendocrine biomarker assay in non-human primates with high {kappa}-receptor homology to humans.  J Pharmacol Exp Ther. 2007;  320 300-6.
• 15 Todtenkopf M S, Marcus J F, Portoghese P S, Carlezon WA J r. Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats.  Psychopharmacology (Berl). 2004;  172 463-70.
• 16 Mague S D, Pliakas A M, Todtenkopf M S, Tomasiewicz H C, Zhang Y, Stevens Jr. W C. et al . Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats.  J Pharmacol Exp Ther. 2003;  305 323-30.
• 17 Thiebot M H, Martin P, Puech A J. Animal behavioural studies in the evaluation of antidepressant drugs. Br J Psychiatry Suppl 1992: 44-50.
• 18 Carlezon WA J r, Beguin C, DiNieri J A, Baumann M H, Richards M R, Todtenkopf M S. et al . Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats.  J Pharmacol Exp Ther. 2006;  316 440-7.
• 19 Lukas G, Brindle S D, Greengard P. The route of absorption of intraperitoneally administered compounds.  J Pharmacol Exp Ther. 1971;  178 562-4.
• 20 Hanes K R. Antidepressant effects of the herb Salvia divinorum: a case report.  J Clin Psychopharmacol. 2001;  21 634-5.
• 21 Munro T A, Goetchius G W, Roth B L, Vortherms T A, Rizzacasa M A. Autoxidation of salvinorin A under basic conditions.  J Org Chem. 2005;  70 10 057-61.
• 22 Lee D Y, Ma Z, Liu-Chen L Y, Wang Y, Chen Y, Carlezon WA J r. et al . New neoclerodane diterpenoids isolated from the leaves of Salvia divinorum and their binding affinities for human kappa opioid receptors.  Bioorg Med Chem. 2005;  13 5635-9.
• 23 Kavvadias D, Monschein V, Sand P, Riederer P, Schreier P. Constituents of sage (Salvia officinalis) with in vitro affinity to human brain benzodiazepine receptor.  Planta Med. 2003;  69 113-7.
• 24 Beguin C, Richards M R, Wang Y, Chen Y, Liu-Chen L Y, Ma Z. et al . Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2).  Bioorg Med Chem Lett. 2005;  15 2761-5.
• 25 Zhang Y, Butelman E R, Schlussman S D, Ho A, Kreek M J. Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors.  Psychopharmacology (Berl). 2005;  179 551-8.
• 26 Fantegrossi W E, Kugle K M, Valdes LJ 3 rd, Koreeda M, Woods J H. Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse.  Behav Pharmacol. 2005;  16 627-33.
• 27 Vonvoigtlander P F, Lahti R A, Ludens J H. U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist.  J Pharmacol Exp Ther. 1983;  224 7-12.
• 28 Wang Y, Tang K, Inan S, Siebert D, Holzgrabe U, Lee D Y. et al . Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo .  J Pharmacol Exp Ther. 2005;  312 220-30.
• 29 McCurdy C R, Sufka K J, Smith G H, Warnick J E, Nieto M J. Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist.  Pharmacol Biochem Behav. 2006;  83 109-13.
• 30 John T F, French L G, Erlichman J S. The antinociceptive effect of salvinorin A in mice.  Eur J Pharmacol. 2006;  545 129-33.
• 31 Capasso R, Borrelli F, Capasso F, Siebert D J, Stewart D J, Zjawiony J K. et al . The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A inhibit enteric cholinergic transmission in the guinea-pig ileum.  Neurogastroenterol Motil. 2006;  18 69-75.
• 32 Valdes LJ 3 rd, Chang H M, Visger D C, Koreeda M. Salvinorin C, a new neoclerodane diterpene from a bioactive fraction of the hallucinogenic Mexican mint Salvia divinorum .  Org Lett. 2001;  3 3935-7.
• 33 Munro T A, Rizzacasa M A. Salvinorins D - F, new neoclerodane diterpenoids from Salvia divinorum, and an improved method for the isolation of salvinorin A.  J Nat Prod. 2003;  66 703-5.
• 34 Shirota O, Nagamatsu K, Sekita S. Neo-clerodane diterpenes from the hallucinogenic sage Salvia divinorum .  J Nat Prod. 2006;  69 1782-6.
• 35 Bigham A K, Munro T A, Rizzacasa M A, Robins-Browne R M. Divinatorins A - C, new neoclerodane diterpenoids from the controlled sage Salvia divinorum .  J Nat Prod. 2003;  66 1242-4.
• 36 Harding W W, Tidgewell K, Schmidt M, Shah K, Dersch C M, Snyder J. et al . Salvinicins A and B, new neoclerodane diterpenes from Salvia divinorum .  Org Lett. 2005;  7 3017-20.
• 37 Munro T A, Rizzacasa M A, Roth B L, Toth B A, Yan F. Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist.  J Med Chem. 2005;  48 345-8.
• 38 Harding W W, Schmidt M, Tidgewell K, Kannan P, Holden K G, Dersch C M. et al . Synthetic studies of neoclerodane diterpenes from Salvia divinorum: selective modification of the furan ring.  Bioorg Med Chem Lett. 2006;  16 3170-4.
• 39 Chavkin C, Sud S, Jin W, Stewart J, Zjawiony J K, Siebert D J. et al . Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations.  J Pharmacol Exp Ther. 2004;  308 1197-203.
• 40 Tidgewell K, Harding W W, Lozama A, Cobb H, Shah K, Kannan P. et al . Synthesis of salvinorin A analogues as opioid receptor probes.  J Nat Prod. 2006;  69 914-8.
• 41 Wasson R G. A new Mexican psychotropic drug from the mint family.  Bot Mus Leafl Harv Univ. 1962;  20 163-93.
• 42 Valdes LJ 3 rd, Diaz J L, Paul A G. Ethnopharmacology of ska Maria Pastora (Salvia divinorum, Epling and Jativa-M.)  J Ethnopharmacol. 1983;  7 287-312.
• 43 Schmidt M D, Schmidt M S, Butelman E R, Harding W W, Tidgewell K, Murry D J. et al . Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates.  Synapse. 2005;  58 208-10.
• 44 Negus S S, Wurrey B A, Mello N K. Sex differences in thermal nociception and prostaglandin-induced thermal hypersensitivity in rhesus monkeys.  J Pain. 2004;  5 92-103.
• 45 Butterweck V, Lieflander-Wulf U, Winterhoff H, Nahrstedt A. Plasma levels of hypericin in presence of procyanidin B2 and hyperoside: a pharmacokinetic study in rats.  Planta Med. 2003;  69 189-92.
• 46 Rold J F. Mushroom madness. Psychoactive fungi and the risk of fatal poisoning.  Postgrad Med. 1986;  79 217-8.
• 47 Scallet A C, Lipe G W, Ali S F, Holson R R, Frith C H, Slikker W J r. Neuropathological evaluation by combined immunohistochemistry and degeneration-specific methods: application to methylenedioxymethamphetamine.  Neurotoxicology. 1988;  9 529-37.
• 48 Tiongson J, Salen P. Mass ingestion of Jimson Weed by eleven teenagers.  Del Med J. 1998;  70 471-6.
• 49 Mowry M, Mosher M, Briner W. Acute physiologic and chronic histologic changes in rats and mice exposed to the unique hallucinogen salvinorin A.  J Psychoactive Drugs. 2003;  35 379-82.
• 50 Schaper D. Legal, herbal hallucinogenic draws teens, critics. In: All things considered. United States of America: National Public Radio; 2006: 7 minutes 25 seconds. 
• 51 Bucheler R, Gleiter C H, Schwoerer P, Gaertner I. Use of nonprohibited hallucinogenic plants: increasing relevance for public health. A case report and literature review on the consumption of Salvia divinorum (Diviner's Sage)?.  Pharmacopsychiatry. 2005;  38 1-5.
• 52 Schmidt M S, Prisinzano T E, Tidgewell K, Harding W, Butelman E R, Kreek M J. et al . Determination of salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization.  J Chromatogr B Analyt Technol Biomed Life Sci. 2005;  818 221-5.
• 53 Pichini S, Abanades S, Farre M, Pellegrini M, Marchei E, Pacifici R. et al . Quantification of the plant-derived hallucinogen Salvinorin A in conventional and non-conventional biological fluids by gas chromatography/mass spectrometry after Salvia divinorum smoking.  Rapid Commun Mass Spectrom. 2005;  19 1649-56.
• 54 Medana C, Massolino C, Pazzi M, Baiocchi C. Determination of salvinorins and divinatorins in Salvia divinorum leaves by liquid chromatography/multistage mass spectrometry.  Rapid Commun Mass Spectrom. 2006;  20 131-6.
• 55 Wolowich W R, Perkins A M, Cienki J J. Analysis of the psychoactive terpenoid salvinorin A content in five Salvia divinorum herbal products.  Pharmacotherapy. 2006;  26 1268-72.
• 56 Gruber J W, Siebert D J, Der Marderosian A H, Hock R S. High performance liquid chromatographic quantification of salvinorin A from tissues of Salvia divinorum Epling & Ja'tiva-M.  Phytochem Anal. 1999;  10 22-5.
• 57 Siebert D J. Localization of salvinorin A and related compounds in glandular trichomes of the psychoactive sage, Salvia divinorum .  Ann Bot (Lond). 2004;  93 763-71.